Welcome to our dedicated page for Tango Therapeutics news (Ticker: TNGX), a resource for investors and traders seeking the latest updates and insights on Tango Therapeutics stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a pioneering biotechnology company focused on discovering and developing novel medicines aimed at targeting cancer vulnerabilities. Founded in 2017 with an initial $55 million Series A investment from Third Rock Ventures, Tango leverages the latest advancements in DNA sequencing and CRISPR-based target discovery. Their goal is to create breakthrough medicines that offer deeper and more sustained benefits than current targeted therapies and to extend the effectiveness of available immuno-oncology agents.
Tango Therapeutics concentrates on three core areas of drug development, each addressing well-defined patient populations with limited treatment options. These areas include:
- Loss of tumor suppressor gene function
- Multiple oncogenic drivers
- Immune evasion
The company’s robust product pipeline includes several promising candidates:
- TNG908 - An MTA-cooperative inhibitor of PRMT5 designed to selectively target cancer cells with MTAP deletions.
- TNG462 - Another advanced preclinical candidate aimed at targeting different cancer types.
- TNG348 - Recently entered Phase 1/2 clinical trials for advanced ovarian, breast, and other cancers with DNA damage repair pathway defects.
- Other discovery programs such as TNG260 and TNG348, focusing on different cancer types with limited current treatment options.
In recent developments, Tango announced dosing the first patient in the TNG348 Phase 1/2 trial, a significant milestone for the company. The trial will assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG348 both as a single agent and in combination with olaparib, a PARP inhibitor.
Tango has established partnerships with several key players in the pharmaceutical industry. These collaborations have significantly bolstered their drug development pipeline. However, recent news highlights the termination of the TNG348 Phase 1/2 clinical trial due to observed toxicity, underscoring the inherent risks in drug development.
For more information, visit www.tangotx.com.
Tango Therapeutics (NASDAQ: TNGX) showcased key findings from its precision oncology portfolio at the AACR 2023 Annual Meeting in Orlando, Florida. Presentations included promising preclinical data for TNG908, a PRMT5 inhibitor targeting glioblastoma, which is currently in a phase 1/2 clinical trial. Additionally, TNG260 showed potential in reversing immune evasion in STK11-mutant cancers and will enter clinical trials later in 2023. The company also highlighted TNG462, another promising PRMT5 inhibitor, and TNG348, a selective USP1 inhibitor for BRCA1/2 mutant cancers, with IND submissions planned. These developments underscore Tango's commitment to targeting critical cancer pathways.
Tango Therapeutics (NASDAQ: TNGX) has received FDA clearance for its IND application for TNG260, a first-in-class inhibitor targeting the CoREST complex, aimed at treating STK11-mutant cancers. This milestone enables the initiation of a Phase 1/2 clinical trial expected in the second half of 2023. STK11 mutations contribute to resistance against standard immunotherapies in cancers such as non-small cell lung cancer. The trial will assess the safety and efficacy of TNG260 in combination with pembrolizumab in patients with various solid tumors having STK11 mutations. This breakthrough underscores Tango's commitment to advancing precision cancer therapies.
Tango Therapeutics (NASDAQ: TNGX) announced key developments in its clinical pipeline and financial results for 2022. The FDA granted Fast Track Designation to TNG462, a next-generation PRMT5 inhibitor, following IND clearance in January 2023. The company initiated a clinical trial for TNG908 and expects updates on its progress in Q2 2023. Financially, Tango reported a net loss of $108.2 million for 2022, compared to $58.2 million in 2021. Collaboration revenue decreased to $24.9 million, down from $26.0 million. Research and development expenses rose to $105.9 million, reflecting increased program advancement costs. Tango ended 2022 with $366.1 million in cash, sufficient to fund operations until 2025.
FAQ
What is the current stock price of Tango Therapeutics (TNGX)?
What is the market cap of Tango Therapeutics (TNGX)?
What is the core focus of Tango Therapeutics?
When was Tango Therapeutics founded?
What are some of the key products in Tango Therapeutics' pipeline?
What recent milestone did Tango Therapeutics achieve?
What happened to the TNG348 clinical trial?
What technologies does Tango Therapeutics leverage in their drug development?
Who are some of Tango Therapeutics' significant partners?
What makes Tango Therapeutics' approach unique?
Where can I find more information about Tango Therapeutics?
What are the risks associated with Tango Therapeutics' drug development?
